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Xanthone has been incorporated for the first time in nanoparticles of poly(d,l-lactide-co-glycolide)
(PLGA). For this purpose the estimation of xanthone content in the nanoparticles is a crucial tool for
guaranteeing the reliability of the results. Thus, a simple spectrophotometric method was validated
according to USP25 and ICH guidelines for its specificity, linearity, accuracy and precision. The meth-
od was found to be specific for xanthone in the presence of nanoparticle excipients. The calibration
curve was linear over the concentration range of 0.5 to 4.0 mg/mL (r > 0.999). Recovery of xanthone
from nanoparticles ranged from 86.5 to 95.9%. Repeatability (intra-assay precision) and intermediate
precision were found to be acceptable with relative standard deviations values (RSD) ranging from 0.3
to 3.0% and from 1.4 to 3.1%, respectively. The method was found to be suitable for the evaluation of
xanthone content in nanoparticles of PLGA.
1. Introduction
Xanthones represent a large group of heterocyclic com-
pounds including natural, semisynthetic and totally syn-
thetic structures (Peres et al. 2000). Among others, anti-
tumoral (Lin et al. 1996a; Kamei et al. 1998), antibacterial
(Hnuma et al. 1996), anti-inflammatory (Lin et al. 1996b),
hepatoprotective (Fernandes et al. 1995), antimalarial
(Ignatushchenko et al. 1997), immunomodulatory (Pinto
and Nascimento 1997; Gonzales et al. 1999), as well as in-
hibitory activities of angiotensine converting enzyme (Chen
and Lin 1992) and monoamine oxidase (MAO) (Thull et al.
1993; Gnerre et al. 2001) have been described. Xanthone
itself was described as a good MAO-A inhibitor (Thull et al.
1994).
Poor aqueous solubility of xanthone and many of its deriva-
tives is a major obstacle for the assessment of pharmacolo-
gical activity of these compounds and for their use in ther-
apy. In general water-insolubility is often associated with
poor bioavaliability (Speiser 1998). One approach to over-
come the difficulty of administration of poorly water-solu-
ble compounds is by incorporation in carrier systems such
as polymeric microparticles and nanoparticles.
By incorporating xanthone or its derivatives in nanoparti-
cles, these poorly water-soluble compounds may be admi-
nistered as nanoparticle aqueous dispersions at concentra-
tions higher than their maximum hidrosolubility. Moreover,
incorporation of these compounds in nanoparticles may al-
low different ways of administration and, simultaneously,
may afford their in vivo protection and targeting.
This study is part of a broader investigation, which aims the
incorporation of xanthone and its derivatives in nanoparti-
cles of poly(dl-lactide-co-glycolide) (PLGA) as well as the
in vitro and in vivo evaluation of the systems. PLGA has
been selected since polyesters, including poly(lactic acid),
poly(glycolic acid) and their copolymers, have emerged as
the most widely studied class of biodegradable polymers
for pharmaceutical use due to their biocompatibility and
biodegradability (Jain et al. 1998). In the present work, we
have used xanthone as a model molecule of this family of
compounds for incorporation in PLGA nanoparticles. For
this purpose the estimation of xanthone content in the na-
noparticles is a crucial step. Thus, the quantification meth-
od of incorporated xanthone constitutes a very important
tool for guaranteeing the reliability of the results. We re-
port here the validation of a simple and accurate spectro-
photometric method for the quantification of xanthone con-
tent in nanoparticles of PLGA according to International
Conference on Harmonisation (ICH) guidelines (Validation
of Analytical Procedures 1998a, b), which are similar to
those established by the United States Pharmacopoeia 25
(USP 25). The method was applied to characterize the le-
vel of xanthone entrapment in PLGA nanoparticles, which
have been prepared for the first time.
2. Investigations, results and discussion
2.1. Validation study
According to the ICH guidelines the specificity of an analy-
tical method is the ability to assess unequivocally the ana-
lyte in the presence of components that may be expected to
be present, such as degradation products, excipients, etc.
(Validation of Analytical Procedures 1998a, b).
In order to evaluate the degradation of xanthone during nano-
particle preparation a TLC was carried out. Two mobile
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phases were used to develop TLC pre-coated plates of silica
gel 60F254 (Merck): petrolbenzine (40–60 C)– Et2O (5 : 5)
and petrolbenzine– EtOAc (5 : 5). Five samples were com-
pared: empty nanoparticles, xanthone, nanoparticles contain-
ing xanthone, mixture of xanthone and nanoparticles con-
taining xanthone (1 : 1) and mixture of xanthone and empty
nanoparticles (1 : 1). Spots were identified by exposure to the
UV light at 254 nm. TLC results showed the absence of
xanthone degradation products, demonstrating that xanthone
remains stable upon nanoparticle preparation in the referred
conditions. Therefore, no degradation products will be pre-
sent in the medium during xanthone quantification.
In order to evaluate the specificity of the analytical method
concerning to the presence of nanoparticle excipients (i.e.
the potential interference of the excipients), a comparison of
the test results from the analysis of xanthone standard solu-
tions spiked with empty nanoparticles (8 mg) with those
obtained from the analysis of xanthone standard solutions
alone was carried out (Table 1). Data analysis was done
using Student’s t test (P ¼ 0.05). No significant difference
was observed between xanthone standard solutions spiked
with empty nanoparticles and the correspondent xanthone
standard solutions alone, once calculated t values were low-
er than the critical t value (2.78, for 4 degrees of freedom
and a confidence limit of 95%).
According to ICH guidelines the linearity of an analytical
method is its ability (within a given range) to obtain test
results that are directly proportional to the concentration of
analyte in the sample (Validation of Analytical Procedures
1998a, b)
To assess linearity, a calibration curve was constructed at
five concentration levels (0.5; 1.0; 2.0; 3.0 and 4.0 mg/mL)
using the linear square regression procedure. The absor-
bance values obtained for three replicate analyses were
averaged at each concentration. Linear regression analysis
was carried out by plotting mean absorbance at 237 nm (y)
versus analyte concentration (x). The calibration curve
showed to be linear over the concentration range examined
with a correlation coefficient (r) > 0.99926 and a coeffi-
cient of determination (R2) > 0.9985, i.e. over 99.85% of
relationship between x and y (Table 2).
According to ICH guidelines the accuracy of an analytical
method expresses the closeness of agreement between a va-
lue (which is accepted either as a conventional true value or
an accepted reference value) and the value found (Valida-
tion of Analytical Procedures 1998a, b). Accuracy is often
calculated as percent recovery by the assay of known,
added amounts of analyte to the sample.
Accuracy of the assay method was determined by spiking
known amounts of xanthone to samples of empty nanoparti-
cles (8 mg) to obtain final xanthone concentrations of 0.5;
1.0; 2.0 and 4.0 mg/mL, corresponding approximately to 13,
26, 52 and 105% of maximum theoretical concentration
(MTC) of 3.8 mg/mL (as defined in the Experimental sec-
tion), respectively. Table 3 summarises the accuracy results,
expressed as percent recovery and relative standard devia-
tion (RSD). Values of recovery ranged from 86.5 to 95.9%.
These results are clearly in agreement to the criteria pro-
posed by Mehta (1989) for the recovery of an analytical
method, which should be preferably higher than 75%.
According to ICH guidelines the precision of an analytical
method expresses the closeness of agreement between a ser-
ies of measurements obtained from multiple sampling of the
same homogeneous sample under the conditions prescribed
(Validation of Analytical Procedures 1998a, b). Precision
may be measured as repeatability, reproducibility and inter-
mediate precision. Repeatability expresses the precision un-
der the same operating conditions over a short interval of
time (also termed intra-assay precision). Reproducibility re-
fers to the use of an analytical procedure in different labora-
tories. Intermediate precision expresses the precision within
laboratory variations (different days, analysts, equipment,
etc). In this work, we have studied repeatability and inter-
mediate precision for different days.
Repeatability was determined by the analysis of five
xanthone standard solutions in the concentration range of
0.5 to 4.0 mg/mL (three replicates each) on the same day.
Intermediate precision was determined by the analysis of
the same standard solutions on three different days. During
this time period, the standard solutions were refrigerated at
4 C. Table 4 summarises repeatability and intermediate
precision results. Obtained RSD values ranged from 0.3 to
3.0% and from 1.4 to 3.1%, respectively, indicating that the
proposed method shows acceptable repeatability and inter-
mediate precision. These results are clearly in agreement to
the criteria proposed by Mehta (1989) and Calpena et al.
(1990) for the precision of an analytical method, whose
RSD should be lower than 10%.
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Table 1: Results of specifity determinations
Xanthone standard solutions Xanthone standard solutions
spiked with empty nanoparticles
Mean concentration
(mg/mL) (n) [SD]
tcalculated*
Theoretical
concentration
(mg/mL)
Actual mean
concentration
(mg/mL) (n) [SD]
1.0 0.9400 (3)
[0.017]
0.9003 (3)
[0.081]
0.832
2.0 1.983 (3)
[0.002]
1.918 (3)
[0.142]
0.784
4.0 3.966 (3)
[0.021]
3.682 (3)
[0.2213]
2.31
* tcalculated ¼ ðx1  x2Þ
s
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
1
n1
þ 1
n2
r ; s ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
ðn1  1Þ s21 þ ðn2  1Þ s22
n1 þ n2  2
s
where x1 and x2 are mean concentrations of the two samples and s1 and s2 standard
deviation values and t has n1 þ n2  2 degrees of freedom.
Table 2: Summary of calibration curve results
Xanthone concentration
(mg/mL)
Mean absorbance RSD (%)
0.5
1.0
2.0
3.0
4.0
0.1087
0.2138
0.4678
0.6899
0.9066
0.772
0.446
1.00
3.23
2.03
Y-intercept
Slope
Correlation coefficient (r)
Coefficient of determination (R2)
0.0035  0.00496a
0.23000  0.00221a
0.99926
0.99852
a Confidence limits of Y-intercept and slope (P ¼ 0.05)
Table 3: Results of accuracy determinations
Xanthone concentration Recovery (%) (n) RSD (%)
(mg/mL) (% of MTC)a
0.5 13 86.5 (3) 3.2
1.0 26 90.0 (3) 1.7
2.0 52 95.9 (3) 3.0
4.0 105 92.1 (3) 2.4
a % of maximum theoretical concentration; RSD Recovery standard deviation
2.2. Application of the validated method
Xanthone content of three different batches of PLGA nano-
particles has been determined by the present validated meth-
od. Table 5 shows incorporation parameters and particle
size of prepared nanoparticles. Incorporation efficiency ran-
ged from 23.9 to 40.8%, with a mean of 32.9%. Mean dia-
meter of xanthone nanoparticles was 117 nm with a narrow
particle size distribution (polydispersity index of 0.06).
3. Experimental
3.1. Materials
Xanthone, PLGA 50 : 50 (MW 50000–75000) and Pluronic F-68 were pur-
chased from Sigma. All solvents and reagents were of analytical grade.
3.2. Nanoparticle preparation and characterization
Xanthone nanoparticles of PLGA were prepared according to a modified
nanodispersion methodology (Fessi et al. 1989). Briefly, 20 mL of an
aqueous medium containing Pluronic F68 (0.25%, w/v) were poured into
20 mL of an acetonic solution containing 125 mg of PLGA polymer and
3 mg of xanthone under moderate stirring, leading to the formation of na-
noparticles. Then, acetone was removed under vacuum. In order to sepa-
rate crystals of nonentrapped xanthone, the nanoparticle dispersion was
filtered through a 0.22 mm membrane (Millipore). To separate soluble
nonentrapped xanthone, the filtrate was subjected to ultracentrifugation at
110000  g for 15 min at 20 C (Beckman UL-80 ultracentrifuge). The
supernatant containing free xanthone was discarded and the pellet was
freeze-dried (Edwards freeze-drier).
Empty nanoparticles were prepared according to the same procedure but
without xanthone in the organic phase.
The mean size and polydispersity index of nanoparticle dispersions were
determined by laser light scattering (Malvern Instr. Zetasizer 5000) gener-
ating a volume-average distribution for analysed data.
3.3. Preparation of sample solution for determination of xanthone in
nanoparticles
Freeze-dried nanoparticles (8 mg) were dissolved in 2 mL of methylene
chloride, followed by precipitation of the polymer by addition of 23 mL of
ethanol. The obtained solution was filtered through a 0.45 mm membrane
(Millipore). The filtrate was diluted with ethanol (1 : 2) and assayed by UV
spectroscopy at 237 nm (Varian spectrophotometer), which corresponds to
the maximum absorption wavelength of xanthone under these conditions.
Considering 100% of xanthone entrapment in nanoparticles, the obtained
sample solution had a maximum theoretical concentration (MTC) of
3.8 mg/mL. All analyses were performed in triplicate and the mean results
are reported.
3.4. Preparation of xanthone standard solutions
Xanthone standard solutions were obtained by dilution of a stock standard
solution (50 mg/mL) with ethanol to give five different concentrations over
the range of interest (0.5 to 4.0 mg/mL).
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Table 4: Results of precision determinations
Theoretical
concentration
(mg/mL)
Mean experimental
concentration
(mg/mL) (n)
SD RSD (%)
Repeatability (intra-assay precision)
0.5 0.467 (3) 0.002 0.3
1.0 0.935 (3) 0.028 3.0
2.0 2.12 (3) 0.021 1.0
3.0 3.02 (3) 0.061 2.0
4.0 3.95 (3) 0.081 2.1
Intermediate precision (different days)
0.5 0.473 (3) 0.010 2.1
1.0 0.941 (3) 0.013 1.4
2.0 2.09 (3) 0.064 3.1
3.0 3.04 (3) 0.046 1.5
4.0 3.94 (3) 0.067 1.7
Table 5: Incorporation parameters and particle size of PLGA
nanoparticles containing xanthone
Theoretical
xanthone
loadinga
% (w/w)
Actual
xanthone
loadingb
% (w/w)
Incorporation
efficiencyc
(%)
Diameter
(nm)
Polidispersity
Indexd
2.4 0.79  0.20 32.9  8.5 117.1  0.6 0.06  0.02
Values express the mean results  SD of three different batches (n ¼ 3)
a Mass of xanthone used in formulation
Mass of polymer used in formulation
 100
b Mass of incorporated xanthone
Mass of freeze - dried nanoparticles
 100
c Xanthone actual loading
Xanthone theoretical loading
 100
d Varies from 0.0 corresponding to a perfect homogeneous dispersion to 1.0 corre-
sponding to a complete heterogeneous dispersion
